CureVac Stock Jumps on News of EU Talks to Supply Covid-19
CureVac and European Commission in Advanced Discussions to Supply up to 405 million doses of potential mRNA-based COVID-19 Vaccine
in talks to sell 225 million doses of its experimental Covid-19 vaccine to the European Commission.
In a statement Thursday, CureVac said it had “concluded exploratory talks outlining an Advanced Purchase Agreement” with the European Commission. Under the terms of the potential deal, the European Commission would buy 225 million doses of the vaccine, with an option of buying another 180 million doses.
Delivery would not take place until the drug was proven safe and effective. CureVac’s Covid-19 vaccine is, like Moderna’s (MRNA) and Pfizer’s (PFE), based on messenger RNA, a relatively novel technology. No messenger-RNA drugs or vaccines are currently approved anywhere in the world. The CureVac vaccine is currently in Phase 1 clinical trials, which the company says will provide data early in the fourth quarter of this year.
The potential deal is the first to be announced by CureVac, which hopes to begin Phase 2b/3 trials of the vaccine in the fourth quarter of this year.
The European Commission has also engaged in exploratory talks with Sanofi (SNY) and GlaxoSmithKline (GSK) about buying 300 million doses of their Covid-19 vaccine, and with Johsnon & Johnson (JNJ) about buying 200 million doses of their Covid-19 vaccine. It has finalized a deal with to buy 300 million doses of AstraZeneca’s (AZN) Covid-19 vaccine.
The European Investment Bank, the European Union’s lending arm, loaned €75 million to CureVac in July to develop and produce vaccines.
“Each round of talks that we conclude with the pharmaceutical industry brings us closer to beating this virus,” said European Commission President Ursula von der Leyen in a statement. “We will soon have an agreement with CureVac.”
www.curevac.com/en/2...ed-covid-19-vaccine/
www.barrons.com...rus-51597933338?siteid=yho...
CureVac and European Commission in Advanced Discussions to Supply up to 405 million doses of potential mRNA-based COVID-19 Vaccine
in talks to sell 225 million doses of its experimental Covid-19 vaccine to the European Commission.
In a statement Thursday, CureVac said it had “concluded exploratory talks outlining an Advanced Purchase Agreement” with the European Commission. Under the terms of the potential deal, the European Commission would buy 225 million doses of the vaccine, with an option of buying another 180 million doses.
Delivery would not take place until the drug was proven safe and effective. CureVac’s Covid-19 vaccine is, like Moderna’s (MRNA) and Pfizer’s (PFE), based on messenger RNA, a relatively novel technology. No messenger-RNA drugs or vaccines are currently approved anywhere in the world. The CureVac vaccine is currently in Phase 1 clinical trials, which the company says will provide data early in the fourth quarter of this year.
The potential deal is the first to be announced by CureVac, which hopes to begin Phase 2b/3 trials of the vaccine in the fourth quarter of this year.
The European Commission has also engaged in exploratory talks with Sanofi (SNY) and GlaxoSmithKline (GSK) about buying 300 million doses of their Covid-19 vaccine, and with Johsnon & Johnson (JNJ) about buying 200 million doses of their Covid-19 vaccine. It has finalized a deal with to buy 300 million doses of AstraZeneca’s (AZN) Covid-19 vaccine.
The European Investment Bank, the European Union’s lending arm, loaned €75 million to CureVac in July to develop and produce vaccines.
“Each round of talks that we conclude with the pharmaceutical industry brings us closer to beating this virus,” said European Commission President Ursula von der Leyen in a statement. “We will soon have an agreement with CureVac.”
www.curevac.com/en/2...ed-covid-19-vaccine/
www.barrons.com...rus-51597933338?siteid=yho...